CURRICULUM VITAE
Wei-Chiang Shen
PERSONAL INFORMATION
Business Address
Business Telephone
FAX
e-mail
Home Address
University of Southern California
School of Pharmacy
1985 Zonal Avenue
Los Angeles, California 90089-9121
(323) 442-1902
(323) 442-1390 or 442-2263
weishen@usc.edu
Home Telephone
2030 Robin Road
San Marino, CA 91108
(626) 309-0613
Place of Birth
Citizenship
Marital Status
China
United States of America (naturalized in 1976)
Married to Daisy Shen, two sons (Howard Shen and Jerry Shen)
EDUCATION
1965
1972
1973
- Department of Chemistry, Tunghai University, Taichung, Taiwan (Bachelor
of Science)
- Department of Chemistry, Boston University, Boston, Massachusetts (Ph.D.,
Major in Bio-organic Chemistry)
- Department of Biological Chemistry, Harvard Medical School, Boston,
Massachusetts (Postdoctoral Fellow).
ACADEMIC APPOINTMENTS
2006-present
1992-2006
1987-92
1983-87
1980-83
1976-80
1973-76
- John A. Biles Professor in Pharmaceutical Sciences, School of Pharmacy,
University of Southern California, Los Angeles
- Professor of Pharmaceutical Sciences, School of Pharmacy, University of
Southern California, Los Angeles
- Associate Professor of Pharmacy, School of Pharmacy, University of
Southern California, Los Angeles
- Associate Professor of Pathology and Pharmacology, School of Medicine,
Boston University, Boston
- Associate Research Professor of Pathology and Pharmacology, School of
Medicine, Boston University, Boston
- Assistant Research Professor of Pathology and Pharmacology, School of
Medicine, Boston University, Boston
- Senior Research Associate, Biochemistry Department, Brandeis University,
Waltham, Massachusetts
Curriculum Vitae, Wei-Chiang Shen
Page 2.
ACADEMIC ADMINISTRATIVE APPOINTMENTS
2003-2006
1993-2000
1989-1992
- Interim Chair, Department of Pharmaceutical Sciences, University of
Southern California School of Pharmacy
- Vice-Chair, Department of Pharmaceutical Sciences, University of Southern
California School of Pharmacy
- Director of Graduate Affairs, University of Southern California School of
Pharmacy
OTHER PROFESSIONAL EXPERIENCE
2008-2012
20072004-2005
2000-2009
2000-2003
2000
-
1999-2004
1998-1999
-
1997-1998
-
1997
-
1996-
-
1996-1998
1986
-
1979-86
-
1983-84
-
Scientific Advisor, Irish Drug Delivery Research Network, Ireland.
Visiting Professor, School of Pharmacy, Lanzhou University, China.
President, Chinese-American Faculty Association of Southern California.
Member, United States Pharmacopeial (USP) Convention.
Member, Biological Safety Committee, University of Southern California.
Member and Interim Chair, Appointment, Promotion and Tenure Committee,
University of Southern California School of Pharmacy.
Member, FDA Radioactive Drug Research Committee #36.
Chair, University Patents and Technology Transfer Committee,
University of Southern California.
Chair, Appointments, Promotions, and Tenure Committee, University of
Southern California School of Pharmacy.
Visiting Professor, School of Pharmacy, National Defense Medical Center,
Taipei, Taiwan.
Member, Committee on Faculty Tenure & Privileges Appeals, University of
Southern California.
Member, University Research Committee, University of Southern California.
Visiting Professor, Department of Pathology, North China Coal Medical
College, Hebei, China.
Visiting Lecturer in Biochemical Toxicology, Department of Biochemistry,
Brandeis University, Waltham, Massachusetts.
Principal, Newton Chinese Language School, Newton, Massachusetts.
AWARDS/HONORS
Tunghai University Distinguished Alumni Award, 2011.
Achievement Award, Chinese-American Faculty Association of Southern California, 2009.
John A. Biles Professorship, USC School of Pharmacy, 2006.
Distinguished Alumni Lecturer, Tunghai University, Taichung, Taiwan, 2003.
Eurand Award (Grand Prize) for Outstanding Novel Research in Oral Drug Delivery, 2002.
Fellow, American Association for the Advancement of Science (AAAS), elected 2000.
Fellow, American Association of Pharmaceutical Scientists (AAPS), elected 1992.
Cancer Research Scholar Award, American Cancer Society (Massachusetts Division),
1982-85.
Postdoctoral Research Fellowship, Massachusetts Heart Association, 1972-73.
Listed in "American Men and Women of Science" and "Marquis Who's Who in America”.
Curriculum Vitae, Wei-Chiang Shen
Page 3.
Graduate students as recipients of the Graduate Student Award in AAPS National Meetings:
Jason Wan (1992), Deven Shah (1994), Cindy Xia (2000), Jennica Zaro (2003), Yun Bai
(2004), Liyun Yuan (2006), Robert Mo (2011) and Yan Wang (2011).
EDITORIAL BOARD
1995-2005
1993-
-Editorial Advisory Board, Pharmaceutical Research
-Editorial Board, Journal of Drug Targeting
JOURNAL REFEREE
American Journal of Physiology, Analytical Biochemistry, Archieves of Biochemistry and
Biophysics, Biochemical Pharmacology, Biochemistry, Biochimica et Biophysica Acta,
Bioconjugate Chemistry, Cancer Research, CRC Critical Review, Diabetes, Drug Discovery
Today, European Journal of Pharmaceutics and Biopharmaceutics, FASEB Journal, Immunology
Letters, International Journal of Pharmaceutics, International Journal of Cancer, Journal of
American Chemical Society, Journal of Cellular Physiology, Journal of Controlled Release,
Journal of Drug Targeting, Journal of Medicinal Chemistry, Journal of Peptide Research, Journal
of Pharmaceutical Sciences, Journal of Pharmacology and Experimental Therapeutics, Medicinal
Research Reviews, Molecular Pharmaceutics, Pharmaceutical Research.
GRANT REVIEWER
National Institutes of Health, USA
National Science Foundation, USA
Medical Research Council of Canada
North Carolina Biotechnology Center
National Health and Medical Research Council of Australia
Science Foundation Ireland
Maryland Technology Enterprise Institute
Frontier and Innovative Research Project, National Taiwan University, Taiwan
Israel Science Foundation
US-Israel Binational Science Foundation
Estonian Science Foundation
Hungarian Scientific Research Fund
Wellcome Trust, UK
Samantha Dickson Brain Tumour Trust, UK
Philip Morris External Research Program
PROFESSIONAL SOCIETIES
American Association for the Advancement of Science (Fellow)
American Association of Pharmaceutical Scientists (Fellow)
Controlled Release Society
Rho Chi Pharmacy Honor Society
Phi Tau Phi Scholastic Honor Society of America
Society of Chinese Bioscientists in America
Page 4.
Curriculum Vitae, Wei-Chiang Shen
EXTERNAL DOCTORAL DISSERTATION EXAMINER
1986
1994, 2000
2002, 2007
Dalhousie University, Halifax, Nova Scotia, Canada
University of the Witwatersrand, Johannesburg, South Africa
National University of Singapore, Singapore
PREVIOUS GRADUATE STUDENTS AND FELLOWS
Name
Degree
Year
Current position
Practice medicine in New York City
Faculty, Boston Univ. School of Med.
Director, Rotta Research Lab, Italy
Faculty, Henan Medical Univ, China
Unidose Systems Co., CA
Favrille, Inc., CA
Faculty, Western University of Health
Sciences, Pomona, CA
Scientist, City of Hope Medical Center
Professor, Shandong, China
Professor, Lanzhou University, China
Associate Professor, Peking University
Assistant Professor, Hiroshima Univ.
Postdoctoral fellows and visiting scholars:
Daming Yang
Wande Li
Stefano Persiani
Xiangtang Du
Donald Chow
Hashem Heiati
Jeff Wang
MD
MD
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
1984
1985
1990
1999
1999
1999
2000
Jun Wu
Yuanjing Qi
Jingman Ni
Qing Xia
Keisuke Oda
Ph.D.
Prof.
Ph.D.
M.D.
Ph.D.
2001
2005
2006
2010
2011
Edward Feener
Jason Wan
Hossein Ekrami
Aaron Yeung
Deven Shah
Mitchell Taub
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
1989
1992
1994
1995
1995
1996
Cindy Xia
Adam Widera
Rita Shen
Jennica Zaro
Tinten Lim
Yun Bai
Maureen Barnes
Fariba N. Cooper
Leena Patel
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
Ph.D.
2000
2003
2005
2005
2005
2006
2006
2006
2007
Rana Bahhady
Liyun Yuan
Nurmamet Amet
Xiaoying Chen
Randall Kenien
Ph.D.
M.D.; Ph.D.
Ph.D.
Ph.D.
Ph.D.
2007
2007
2008
2011
2012
Ph.D. students:
Faculty, Harvard Medical School
Vice President, WuXi AppTec
Surza’s Medical Investment Group
Church Minister, Hawaii
Senior Director, GalaxoSmithKline
Senior Research Fellow, BoehringerIngelheim
Senior Scientist, Takeda-Millenium
QC Chemistry Manager, Grifols
Faculty, National Taiwan University
Faculty, USC
Senior Scientist, Nanotrope
Faculty, PCOM School of Pharmacy
Senior Scientist, Biogen-Idec
Research Scientist, Eli Lilly
Scientific Writer, Allergan
Pharmaceuticals
Practice Pharmacy
Physician Fellow, USC Sch of Medicine
Amgen
Senior Scientist, Pfizer Inc.
Olympus
Page 5.
Curriculum Vitae, Wei-Chiang Shen
Robert Mo
Yan Wang
Ph.D.
Ph.D.
2012
2012
Senior Scientist, Pfizer Inc.
Scientist, Amgen
MS
MS
Pham.D./MS
MS
MS
MS
MS
MS
MS
MS
MS
MS
MS
MS
MS
MS
1990
1992
1999
1999
2000
2001
2003
2004
2006
2006
2008
2009
2009
2010
2011
2012
Returned to Taiwan
Family business (India)
Pharmacist (Pittsburgh)
Scientific Writer, Amgen
Pharmacist (Los Angeles)
Ph.D. Student, UC Davis
Phoenix Pharmaceutics (California)
Ph.D. Student, Tsinghua Univ. (Taiwan)
Ph.D. Student, Taipei Medical Univ.
Genentech, Oceanside, CA
Res. Assistant, USC
Medical Instrument Business
Amgen
Project Manager, Mello Biotech
Ph.D. student, USC
Clinical Trial Coordinator, UCLA
MS students:
Yi-Jing Lin
Krishna Srivastava
Laura Honeycutt
Karin Beloussow
Li Wang
Daphne Wu
Wendy Lin
Chris Hsu
Claire Lai
Jacqueline E. Vekich
Hsin-Fan Lee
Ling (Michelle) Ren
Matthew A. Janson
Max Kuo
Yu-Sheng (Sam) Chen
Manali Shah
Current Ph.D. students:
Likun (Paul) Fei
Yu-Sheng Chen
Juntang Shao
Zoe Folchman-Wagner
Yuqian Liu
Li Zhou
Current MS students:
Sean Wang
Visiting students:
Fariba Nouroziyan (Uppsala University, Sweden), 2000.
Thuy Tran (Uppsala University, Sweden), 2005.
Christina Schlesinger (UC Berkeley), 2011.
Julia Nilsson (Lund’s Institute of Technology, Sweden), 2011 – 2012.
Chunmeng Sun (China Pharmaceutical University, China), 2011 – 2013.
Tze-Harn Yeh (National Taiwan University, Taiwan), 2013-2014.
CURRENT RESEARCH INTERESTS
Curriculum Vitae, Wei-Chiang Shen
1.
2.
3.
4.
5.
6.
7.
Page 6.
Endocytosis and intracellular processing of macromolecules in mammalian cells.
Transferrin receptor-mediated transcytosis in epithelial cells.
Reversible aqueous lipidization (REAL) of polypeptides and oligonucleotides
Oral and pulmonary delivery of peptide and protein drugs.
Design of recombinant fusion proteins for therapeutic applications.
Cell-penetrating peptides (CPPs): mechanisms and applications.
CPP-mediated siRNA delivery
INVITED SPEAKER IN RECENT NATIONAL AND INTERNATIONAL CONFERENCES
(2001 - PRESENT)
“Reversible lipidization of peptides and proteins.” Conference on Barriers to Entry: New
Directions in Drug Delivery Systems, Los Angeles, CA, March, 2001.
“Transferrin receptor-mediated transcytosis for oral delivery of insulin.” 28th International
Symposium on Controlled Release of Bioactive Materials, San Diego, CA, June, 2001.
“Reversible aqueous lipidization of peptide drugs.” US-Japan Conference on Drug Development
and Rational Drug Therapy, Tokyo, Japan, August, 2001.
“Transferrin receptor-mediated transcytosis for oral delivery of insulin.” Symposium on Oral
Delivery Technologies for Biopharmaceutical Products, Industrial Technology Research
Institute, Hsin-Chu, Taiwan, November, 2001.
“Reversible lipidization for oral delivery of peptide drugs.” Symposium on Oral Delivery
Technologies for Biopharmaceutical Products, Industrial Technology Research Institute, HsinChu, Taiwan, November, 2001.
“Transferrin Receptor Mediated Transport in GI Absorption.” AAPS Pharmaceutics and Drug
Delivery Conference, Arlington, VA, April, 2002.
“Reversible lipidization for oral delivery of peptide drugs.” 29th Annual Meeting of the
Controlled Release Society, Seoul, Korea, July, 2002.
“Transferrin Receptor-Mediated Transcytosis for Pulmonary Drug Delivery.” Nasal and
Pulmonary Drug Delivery Conference VII, Barcelona, Spain, September, 2003.
“Recombinant Transferrin Fusion Proteins for Oral Delivery of Protein Drugs.” 2nd Forum on
Cross-Straits Chemical Biology, Biotechnology and Medicine Development, Xiamen, China,
July, 2004.
“Membrane Transduction Peptides as Potential Carriers for Cytoplasmic Delivery of
Macromolecular Drugs.” 10th SCBA International Symposium, Beijing, China, July, 2004.
“Recombinant Transferrin Fusion Proteins for Oral Delivery of Protein Drugs.” U.S./Taiwan
Nutraceutical, Medical, Biotech, and Genomics Conference, Pasadena, CA, October, 2004.
Curriculum Vitae, Wei-Chiang Shen
Page 7.
“Membrane Transduction Peptides as Potential Carriers for Cytosolic Delivery of
Macromolecular Drugs.” 3rd Forum on Cross-Straits Chemical Biology, Biotechnology and
Medicine Development, Taichung, Taiwan, July, 2005.
“Recombinant Transferrin-G-CSF Fusion proteins as Oral Myelopoietic Agents.” 2006
International Conference in Biotech and Pharmaceutical Science and Technology, San Diego,
CA, December, 2006.
“Oral Delivery of Recombinant Transferrin-Fusion Proteins.” 13th International Symposium on
Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February, 2007.
“Design of Recombinant Transferrin-Granulocyte Colony-Stimulating Factor Fusion Proteins for
Oral Delivery.” GEM4 Conference on Cancer, Singapore, July, 2007.
“Cell Penetrating Peptides as Vectors for Pulmonary Delivery of Insulin.” Biomedical
Engineering Society 2007 Annual Fall Meeting, Los Angeles, CA, September, 2007.
“Design of Recombinant G-CSF-Transferrin Fusion Protein for Oral Delivery.” 7th International
Conference and Workshop on Biological Barriers and Nanomedicine, Saarbrueken, Germany,
February, 2008.
“Reversible Aqueous Lipidization (REAL) of Peptide and Protein Drugs.” BIT’s First Annual
Protein and Peptide Conference (PepCon2008), Shenzhen, China, April, 2008.
“Design of Recombinant G-CSF-Transferrin Fusion Proteins for Oral Delivery.” 3rd Annual
Engineering Protein Therapeutics for Delivery, PEGS Conference, Boston, MA, May, 2008.
“Protein and Peptide Drug Delivery: An 85 Year Old Challenge to the New Generation of Drugs
from Pharmaceutical Industry.” Monte Jade Science and Technology Association Bio Forum,
Santa Clara, CA, May, 2008.
“Reversible Lipidized Interferon-alpha as an Anti-Hepatitis Drug.” 5th Conference of ChannelBridge Chemistry, Biology and Material Science, Tainan, Taiwan, July, 2008.
“Reversible Lipidization of Protein and Peptide Drugs: A Study of Lipidized Interferon-alpha.”
Drug Delivery Technology Asia 2008, Seoul, South Korea, October, 2008.
“Cell-Penetrating Peptides: from Peptide Chemistry to Drug Delivery.” Symposium in Honor of
Professor Richard A. Laursen, Boston University, Boston, October, 2009.
“Effect of Spacer Insertion on the Production, Biological Activity, and Pharmacokinetics of
Recombinant Bifunctional Fusion Proteins.” CHI PepTalk Conference, San Diego, January,
2010.
“Recombinant Granulocyte Colony-Stimulating Factor and Transferrin Fusion Proteins as
Myelopoietic Agents.” PepCon 2010, Beijing, China, March, 2010.
“Production, Pharmacokinetics and Oral Delivery of Bifunctional Transferrin Fusion Proteins.”
Novo Nordisk Oral Protein Delivery Symposium, Copenhagen, Denmark, December, 2010.
Curriculum Vitae, Wei-Chiang Shen
Page 8.
“Recombinant Transferrin fusion Proteins for the Activation of Protein Precursors in Liver: The
Conversion of Proinsulin to Insulin as a Transferrin Fusion Protein in Hepatoma Cells.” CHI
PepTalk Conference, San Diego, January, 2011.
“Cell-Penetrating Peptides for Cytosolic or Nuclear Transport.” PepCon 2011, Beijing, China,
March, 2011.
“Pharmacokinetics of Recombinant Bifunctional Fusion Proteins.” Gordon Research Conference
– Drug Metabolism, Holderness, New Hampshire, July, 2011.
“Fusion Proteins for Improving Absorption and Disposition of Protein Drugs: Transferrin as an
Active Carrier Domain.” AAPS Annual Meeting, Washington, DC, October, 2011.
“Pharmacokinetics and pharmacodynamics of Recombinant Bifunctional Fusion Proteins.” 2nd
Annual World Congress of Molecular and Cell Biology, Beijing, China, May, 2012.
“Recombinant Proinsulin-Transferrin Fusion Protein as an Insulin Prodrug for the Selective
Inhibition of Hepatic Glucose Production.” CHI PepTalk Conference, Palm Springs, January,
2013.
“Effect of Linker on Pharmacokinetics and Pharmacodynamics of Bifunctional Fusion Proteins.”
PepCon-2013, Suzhou, China, March, 2013.
“Recombinant Proinsulin-Transferrin Fusion Protein as an Insulin Prodrug for the Selective
Inhibition of Hepatic Glucose Production.” Pharmaceutica-2013, Chicago, April 2013.
“Recombinant Proinsulin-Transferrin Fusion Protein as a Model of Peptide Prodrug for the
Selective Activation in the Liver.” AAPS National Biotech Conference, San Diego, May 2013.
“Recombinant Proinsulin-Transferrin Fusion Protein for the Treatment of Diabetes.” The 6th
China Medicinal Biotech Forum, Shenzhen, China, September 26th, 2013.
INVITED SEMINAR PRESENTATIONS
2005:
Pfizer, Inc., St. Louis, MO, June 14.
Tunghai University, Taiwan, July 19.
Industrial Technology Research Institute, Taiwan, July 25.
National Taiwan University, Taiwan, July 27.
National Defense Medical Center, Taiwan, July 28.
Wyeth Pharmaceuticals, Cambridge, MA, August 10.
University of California, Irvine, CA, October 10.
China Pharmaceutical University, China, November 4.
2006:
Boston University, Boston, MA, May 10.
Hoffman La Roche, Inc., Nutley, NJ, September 1.
University of Tennessee, Memphis, TN, October 16.
2007:
Curriculum Vitae, Wei-Chiang Shen
National Tsinghua University, Taiwan, January 17.
National Taiwan University, Taiwan, January 22.
City of Hope Medical Center, Duarte, CA, March 8.
Pfizer, Inc., St. Louis, MO, March 16.
Amylin Pharmaceuticals, Inc. La Jolla, CA, August 17.
Ohio State University, Columbus, OH, October 9.
Jiangsu University, China, October 15.
China Pharmaceutical University, China, October 17.
Lanzhou University, China, October 22.
Allergan, Inc., Irvine, CA, December 4.
2008:
Bath University, Bath, UK, March 3.
Cardiff University, Cardiff, UK, March 5.
Wheaton College, Norton, MA, October 3.
National Taiwan University, Taiwan, October 27.
2009:
Genentech, South San Francisco, CA, January 28.
University of North Carolina, Chapel Hill, NC, March 18.
Trinity College, Dublin, Ireland, April 24.
Pfizer, Inc., St. Louis, MO, November 18.
2010:
National Defense Medical Center, Taiwan, March 19.
Peking University, Beijing, China, March 22.
China Pharmaceutical University, China, May 17.
Trinity College, Dublin, Ireland, July 5.
2011:
University of Massachusetts, Amherst, MA, March 3.
Fudan University School of Pharmacy, Shanghai, China, March 28.
University College Dublin, Dublin, Ireland, October 18.
2012:
Liaocheng Hospital Medical Center, Shandong, China, May 14.
Taipei Medical University, Taipei, Taiwan, June 4.
National Taiwan University, Taipei, Taiwan, October 29.
Taipei Medical University, Taipei, Taiwan, Oct. 30.
2013:
AAPS Southern California Pharmaceutical Discussion Group, Irvine, February 21.
University of North Carolina, Chapel Hill, NC, April 15.
University of Macau, Macau, September 24.
Ventria Biosciences, Fort Collins, CO, October 15.
Page 9.
Curriculum Vitae, Wei-Chiang Shen
Page 10.
INVENTIONS AND PATENTS
US Patent No. 4,631,190: "Acidity-Sensitive Spacer Molecule to Control the Release of
Pharmaceuticals from Molecular Carriers."
US Patent No. 5,144,001: "Acidity-Sensitive Spacer Molecule to Control the Release of
Pharmaceuticals from Molecular Carriers."
US Patent No. 4,701,521: "Method of Effecting Cellular Uptake of Molecules."
US Patent No. 4,847,240: "Method of Effecting Cellular Uptake of Molecules."
US Patent No. 5,254,342: "Compositions and Methods for Enhanced Transepithelial and
Transendothelial Transport of Active Agents."
US Patent No. 5,907,030: "Methods and Compositions for Lipidization of Hydrophilic
Molecules."
US Patent No. 5,936,092: “Methods and Compositions for Lipidization of Hydrophilic
Molecules.”
US Patent No. 6,093,692: “Methods and Compositions for Lipidization of Hydrophilic
Molecules.”
US Patent No. 6,225,445: “Methods and Compositions for Lipidization of Hydrophilic
Molecules.”
US Patent No. 6,590,071: “Reversible Aqueous pH Sensitive Lipidization Reagents,
Compositions and Methods of Use.”
US Patent No. 7,052,704: “Methods and Compositions for Lipidization of Hydrophilic
Molecules.”
US Patent No. 7,943,733: “Spacers to Increase the Expression of Recombinant Fusion Proteins.”
US Patent No. 7,956,158: “Fusion Proteins with Cleavable Spacers and Uses Thereof.”
US Patent No. 8,188,032: “G-CSF-Tranferrin Fusion Proteins.”
US Patent No. 8,378,076: “Spacers to Increase the Expression of Recombinant Fusion Proteins.”
US Patent No. 8,486,384: “Lipidized interferon and methods of treating viral hepatitis.”
US Patent Pending No. PCT/US13/174,520: “Methods for Uses of Protein Precursors as
Prodrugs.”
Curriculum Vitae, Wei-Chiang Shen
Page 11.
US Provisional Appln No. 61/754,448: “Design of pH-sensitive Oligopeptide Complexes for
Drug Release under Mildly Acidic Conditions.”
PUBLICATIONS
Research papers:
1. Wang TSC, Liang YC and Shen WC: Method of extraction and analysis of higher fatty acids and
triglycerides in soils. Soil Sci 107:181-187, 1969.
2. Laursen RA, Baumann JB, Linsley KB and Shen WC: Inactivation of fumarase by
bromomesaconate, an active site-directed irreversible inhibitor. Arch Biochem Biophys 130:688689, 1969.
3. Laursen RA, Shen WC and Zahka KG: Bromomesaconic and bromocitraconic acids. Potential
Active Site Labeling Reagents for Dicarboxylic Acid Metabolizing Enzymes. J Med Chem 14:619621, 1971.
4. Shen WC, Mauck L and Colman RF: Physicochemical properties of the DPN- specific isocitrate
dehydrogenase of pig heart. J Biol Chem 249:7942-7949, 1974.
5. Shen WC and Van Vunakis H: Nicotine and its metabolites IV. Formation of the nicotine analogue
of DPN by pig brain DPNase. Res Commun Chem Pathol Pharmacol 9:405-412, 1974.
6. Shen WC and Van Vunakis H: The formation and characterization of the nicotine analog of
triphosphopyridine nucleotide. Biochemistry 13:5362-5367, 1974.
7. Shen WC and Colman RF: Cyanate modification of essential lysyl residues of the DPN-specific
isocitrate dehydrogenase of pig heart. J Biol Chem 250:2973-2978, 1975.
8. Shen WC, Franke J and Van Vunakis H: Nicotinamide nucleotide analogues of nicotine and
cotinine -- enzymic studies. Biochem Pharmacol 26:1835-1840, 1977.
9. Shen WC, Greene KM and Van Vunakis H: Detection by radioimmunoassay of nicotinamide
nucleotide analogues in tissues of rabbits injected with nicotine and cotinine. Biochem Pharmacol
26:1841-1846, 1977.
10. Shen WC and Ryser H J-P: Conjugation of poly-l-lysine to albumin and horseradish peroxidase: A
novel method of enhancing the cellular uptake of proteins. Proc Natl Acad Sci USA 75:1872-1876,
1978.
11. Ryser H J-P, Shen WC and Merk FB: Membrane transport of macromolecules: New carrier
functions of proteins and poly(amino acids). Life Sci 22:1253-1260, 1978.
12. Ryser H J-P and Shen WC: Conjugation of methotrexate to poly(l-lysine) increases drug transport
and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 75:3867-3870, 1978.
Curriculum Vitae, Wei-Chiang Shen
Page 12.
13. Shen WC and Ryser H J-P: Poly(l-lysine) and poly(d-lysine) conjugates of methotrexate: Different
inhibitory effect on drug resistant cells. Mol Pharmacol 16:614-622, 1979.
14. Ryser H J-P and Shen WC: Conjugation of methotrexate to poly(l-lysine) as a potential way to
overcome drug resistance. Cancer 45:1207,-1211, 1980.
15. Shen WC and Ryser H J-P: Selective protection against the cytotoxicity of methotrexate and
methotrexate-poly(lysine) by thiamine pyrophosphate, heparin and leucovorin. Life Sci 28:12091214, 1981.
16. Shen WC and Ryser H J-P: Cis-aconityl spacer between daunomycin and macromolecular carrier: A
model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys
Res Commun 102:1048-1054, 1981.
17. Shen WC and Ryser H J-P: Poly(L-lysine) has different membrane transport and drug-carrier
properties when complexed with heparin. Proc Natl Acad Sci USA 78:7589-7593, 1981.
18. Ryser H J-P, Drummond I and Shen WC: The cellular uptakes of horseradish peroxidase and its
poly(lysine) conjugate by cultured fibroblasts are qualitatively similar despite a 900-fold difference
in rate. J Cell Physiol 113:167-178, 1982.
19. Ryser H J-P, Morad N and Shen WC: Interaction of heparin with cultured cells: Possible role of
fibronectin in uncoupling surface binding and endocytosis. Cell Biol Internat'l Reports 7:923-930,
1983.
20. Shen WC and Ryser H J-P: Selective killing of Fc-receptor-bearing tumor cells through endocytosis
of a drug-carrying immune complex. Proc Natl Acad Sci USA 81:1445-1447, 1984.
21. Morad N, Ryser H J-P and Shen WC: Binding sites and endocytosis of heparin and poly(lysine) are
changed when the two molecules are given as a complex to Chinese hamster ovary cells. Biochim
Biophys Acta 801:117-126, 1984.
22. Shen WC, Yang D and Ryser H J-P: Colorimetric determination of microgram quantities of
polylysine by trypan blue precipitation. Anal Biochem 142:521-524, 1984.
23. Shen WC, Ryser H J-P and LaManna L: Disulfide spacer between methotrexate and poly(D-lysine):
A probe for exploring the reductive process in endocytosis. J Biol Chem 260:10905-10908, 1985.
24. Ballou B, Reiland JM, Levine G, Shen WC, Ryser H J-P, Solter D and Hakala TR: Tumor location
and drug targeting using a monoclonal antibody (anti-SSEA-1) and antigen-binding fragments. J
Surg Oncol 31:1-12, 1986.
25. Li W, Ryser H J-P and Shen WC: Altered endocytosis in a mutant of LM-fibroblasts defective in
cell-cell fusion. J Cell Physiol 126:161-166, 1986.
26. Shen WC and Ryser H J-P: Disulfide and other spacers for the intracellular release of drugs from
polymeric carriers. Polymer Preprints 27:9-10, 1986.
27. Ryser H J-P, Shen WC and Morad N: Poly(lysine): Heparin complexes as potential drug-carriers for
receptor-mediated endocytosis. Polymer Preprints 27:15-16, 1986.
Curriculum Vitae, Wei-Chiang Shen
Page 13.
28. Shen WC, Ballou B, Ryser H J-P and Hakala TR: Targeting, internalization, and cytotoxicity of
methotrexate-monoclonal anti-SSEA-1 antibody conjugates in cultured F-9 teratocarcinoma cells.
Cancer Res 46:3912-3916, 1986.
29. Ryser H J-P, Mandel R, Hacobian A and Shen WC: Methotrexate-poly (lysine) as a selective agent
for mutants of Chinese hamster ovary cells defective in endocytosis. J Cell Physiol 135:277-284,
1988.
30. Ryser HJ-P, Li W, Mandel R and Shen WC: A mutant of LM fibroblast defective in fluid-phase but
competent in receptor-mediated endocytosis. J Cell Physiol 137:490-496, 1988.
31. Persiani S, Ballou B, Shen WC, Ryser HJ-P, Reiland JM and Hakala TR: In vivo antitumor effect of
methotrexate conjugated to anti-SSEA-1 monoclonal IgM antibody on MH-15 mouse
teratocarcinoma. Cancer Immunol Immunotherap 29:167-170, 1989.
32. Shen WC, Du X, Feener EP and Ryser HJ-P: The intracellular release of methotrexate from a
synthetic drug carrier system targeted to Fc receptor-bearing cells. J Controlled Release 10:89-96,
1989.
33. Persiani S and Shen WC: Increase of poly(lysine) uptake but not fluid phase endocytosis in
neuraminidase pretreated Madin-Darby canine kidney (MDCK) cells. Life Sci 45:2605-2610, 1989.
34. Du X, Yeung A and Shen WC: A cytostatic protein isolated from the conditioned medium of mouse
monocytic leukemia WEHI-3 cell cultures. Immunol Lettrs 23:119-124, 1989.
35. Shen WC, Wan J and Shen D: Proteolytic processing in a non-lysosomal compartment is required
for transcytosis of protein-polylysine conjugates in cultured Madin-Darby canine kidney cells.
Biochem Biophys Res Commun 166:316-323, 1990.
36. Shen WC: Acid-sensitive dissociation between poly(lysine) and histamine-modified poly(glutamate)
as a model for the drug-releasing from carriers in endosomes. Biochim Biophys Acta 1034:122-124,
1990.
37. Wan J, Persiani S and Shen WC: Transcellular processing of disulfide-and thioether-linked
peroxidase polylysine conjugates in cultured MDCK epithelial cells. J Cell Physio 145:9-15, 1990.
38. Feener EP, Shen WC and Ryser HJ-P: Cleavage of disulfide bond in endocytosed macromolecules.
J Biol Chem 265:18780-18785, 1990.
39. Shen WC, Wan J, Persiani S and Shen D: Poly(amino acids) as biodegradable carriers in
transepithelial drug delivery systems. Polymer Preprints 31:163-164, 1990.
40. Shen WC, Persiani S and Srivastava K: Chemical linkages in drug-antibody conjugation. BioPharm
3:16-22, 1990.
41. Shen WC, Persiani S, Ballou B and Hakala TR: Antibodies as drug carriers for solid tumor:
evaluation of drug-anti-SSEA-1 conjugates in the treatment of teratocarcinoma. Targeted Diagn Ther
3: 289-304, 1990.
Curriculum Vitae, Wei-Chiang Shen
Page 14.
42. Lin YJ and Shen WC: Effects of deoxycholate on the transepithelial transport of sucrose and
horseradish peroxidase in filter-grown MDCK cells. Pharm Res 8:498-501, 1991.
43. Persiani S, Yeung A, Shen WC and Kennedy AR: Polylysine conjugates of Bowman-Birk protease
inhibitor as targeted anticarcinogenic agents. Carcinogenesis 12: 1149-1152, 1991.
44. Mandel R, Ryser HJP, Niaki B, Ghani F and Shen WC: Isolation of variants of chinese hamster
ovary cells with abnormally low levels of GSH: Decreased ability to cleave endocytosed disulfide
bonds. J Cell Physiol 149:60-65, 1991.
45. Taub M and Shen WC: Polarity in the transcytotic processing of apical and basal membrane-bound
peroxidase-polylysine conjugates in MDCK cells. J Cell Physiol 150:283-290, 1992.
46. Wan J, Taub ME, Shah D and Shen WC: Brefeldin A enhances receptor-mediated transcytosis of
transferrin in filter-grown Madin-Darby canine kidney cells. J Biol Chem 267:13446-13450, 1992.
47. Ballou B, Jaffe R, Persiani S, Shen WC, Langone JJ, Sands H, Reidland JM, Curley J and Hakala
TR: Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and
MOPC 104E in mouste teratocarcinomas and normal tissues. Cancer Immunol Immunother 35:251254, 1992.
48. Ekrami H, Kennedy AR, Witschi H and Shen WC: Cationized Bowman-Birk protease inhibitor as a
targeted cancer chemopreventive agent. J Drug Targeting 1:41-49, 1993
49. Taub ME and Shen WC: Regulation of pathways within cultured epithelium cells for the
transcytosis of basalmembrane-bound peroxidase-polylysine conjugate. J Cell Sci 106:1313-1321,
1993.
50. Shah D and Shen WC: The establishment of polarity and enhanced transcytosis of transferrin
receptors in enterocyte-like caco-2 cells. J Drug Targeting 2:93-99, 1994.
51. Taub ME, Wan J and Shen WC: Transepithelial transport of tyramine across filter-grown MDCK
cells via a poly (D-lysine) carrier. Pharm Res 11:1250-1256, 1994.
52. Ekrami H and Shen WC: Carbamylation decreases the cytotoxicity but not the drug-carrier
properties of polylysines. J Drug Targeting 2:469-475, 1995.
53. Ekrami H, Kennedy AR and Shen WC: Disposition of positively changed Bowman-Birk protease
inhibitor conjugates in mice: Influence of protein conjugate charge density and size on lung
targeting. J Pharm Sci 84:456-461, 1995.
54. Gladysheva IP, Polekhina OV, Shen WC, Shevchenko AA, Kazanskaya NF and Larionova NI:
Structure and biological properties of Bowman-Birk soybean proteinase inhibitor conjugate with
block copolymer of ethylene oxide and propylene oxide. Biochemistry (Moscow) 60:385-391, 1995.
55. Ekrami HM, Kennedy AR and Shen WC: Water soluble fatty acid derivatives as acylating agents
for reversible lipidization of polypeptides. FEBS Lett 371:283-286, 1995.
56. Shah D and Shen WC: The paradox of transferrin receptor-mediated drug delivery - intracellular
targeting or transcellular transport? J Drug Targeting 3:243-245, 1995.
Curriculum Vitae, Wei-Chiang Shen
Page 15.
57. Honeycutt L, Wang J, Ekrami H and Shen WC, Comparison of pharmacokinetic parameters of a
polypeptide, the Bowman-Birk protease inhibitor (BBI), and its plamitic acid conjugate. Pharm
Res 13:1372-1376, 1996.
58. Shah D and Shen WC, Transepithelial delivery of an insulin-transferrin conjugate in enterocytelike Caco-2 cells. .J Pharm Sci, 85:1306-1311, 1996.
59. Hamm-Alvarez SF, Sonee M, Loran-Goss K and Shen WC, Paclitaxel and nocodazole
differentially alter endocytosis in cultured cells. Pharm Res 13:1647-1656, 1996.
60. Yeung AK, Basu SK, Wu SK, Chun C, Okamoto CT, Hamm-Alvarez S, von Grafenstein H, Shen
WC, Kim KJ, Bolger MB, Haworth IS, Ann DK and Lee VHL: Molecular identification of a role
for tyrosine 167 in the function of the human inestinal proton-coupled dipeptide transporter
(hPepT1) Biochem Biophys Res Commun 250: 103-107, 1998.
61. Wang J, Shen D and Shen WC: Preparation, purification, and characterization of a reversibly
lipidized desmopressin with potentiated anti-diuretic activity. Pharm Res 16: 1674-1679, 1999.
62. Wang J and Shen WC: Gastric retention and stability of lipidized Bowman-Birk protease inhibitor
in mice. Int J Pharm 204: 111-116, 2000.
63. Xia, C, Wang J and Shen WC: Hypoglycemic effect of insulin-transferrin conjugate in
streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 295: 594-600, 2000. (PMID 11046093).
64. Shen WC, Beloussow K, Meirim MG, Neuse EW and Caldwell G: Antiproliferative activity of
polymer-bound, monoamine-coordinated platinum complexes against LNCaP human metastatic
prostate adenocarcinoma cells. J Inorg Organometal Polym 10: 51-60, 2000.
65. Caldwell G, Meirim MG, Neuse EW, Beloussow K and Shen WC: Antiproliferative activity of
polyaspartamide-ferrocene conjugates containing the biofissionable carboxamide function in the
anchoring links. J Inorg Organometal Polym 10: 93-101, 2000.
66. Xia C and Shen WC: Tyrphostin-8 enhances transferrin receptor-mediated transcytosis in Caco-2
cells and increases hypoglycemic effect of orally administered insulin-transferrin conjugate in
diabetic rats. Pharm Res 18: 191-195, 2001. (PMID 11405290).
67. Du X, Beloussow K and Shen WC: Bowman-Birk protease inhibitor and its palmitic acid conjugate
prevent 7,12-dimethylbenz[a]anthracene-induced transformation in cultured mouse mammary glands.
Cancer Lett 164: 135-141, 2001.
68. Gladysheva IP, Polekhina OV, Karmakova TA, Nemtsova ER, Yakubovskaya RI, Shen WC,
Kennedy AR and Larionova NI: Potential of block copolymer- and imuno-conjugates for tumortargeted delivery of Bowman-Birk soybean proteinase inhibitor. J Controlled Release 74: 303-308,
2001.
69. Beloussow K, Wang L, Wu J, Ann D and Shen WC: Recombinant arginine deiminase as a potential
anti-angiogenic agent. Cancer Lett 183: 155-162, 2002.
Curriculum Vitae, Wei-Chiang Shen
Page 16.
70. Wang J, Wu D and Shen WC: Structure-activity relationship of reversibly lipidized peptides: Studies
of fatty acid-desmopressin conjugates. Pharm Res 19: 609-614, 2002.
71. Widera A, Beloussow K, Kim KJ, Crandall ED and Shen WC: Phenotype-dependent synthesis of
transferrin receptor in rat alveolar epithelial cell monolayers. Cell Tissue Res 312: 313-318, 2003.
72. Shen LJ, Lin WC, Beloussow K and Shen WC: Resistance to the anti-proliferative activity of
recombinant arginine deiminase in cell culture correlates with the endogenous enzyme,
argininosuccinate synthetase. Cancer Lett 191: 165-170, 2003.
73. Larionova NV, Malykh EV, Villemson AL, Krasota AJu, Duchene D, Ollivon M, Gernet M,
Belousova RV, Shen WC and Larionova NI: Effect of membranotropic and mucoadhesive
formulations of protein proteinase inhibitors on bovine herpes virus-1 reproduction. Int J Pharm 256:
191-198, 2003.
74. Wang J, Chow D, Heiati H and Shen WC: Reversible lipidization for the oral delivery of salmon
calcitonin. J Controlled Release 88: 369-380, 2003.
75. Shen LJ, Lin WC, Beloussow K, Hosoya K, Terasaki T, Ann DK and Shen WC: Arginine deiminase
inhibits NO production via iNOS, but not eNOS in endothelial cells. Biochem Pharmacol 66: 19451952, 2003.
76. Widera A, Kim KJ, Crandall ED and Shen WC: Transcytosis of GCSF-transferrin across rat
alveolar epithelial cell monolayers. Pharm Res 20: 1231-1238, 2003.
77. Zaro JL and Shen WC: Quantitative comparison of membrane transduction and endocytosis of
oligopeptides. Biochem Biophys Res Commun 307: 241-247, 2003.
78. Kennedy AR, Kritchevsky D and Shen WC: Effects of spermine-conjugated Bowman-Birk inhibitor
(spermine-BBI) on carcinogenesis and cholesterol biosynthesis in mice. Pharm Res 20: 1908-1910,
2003.
79. Widera A, Bai Y and Shen WC: The transepithelial transport of a G-CSF-transferrin conjugate in
Caco-2 cells and its myelopoietic effect in BDF1 mice. Pharm Res 21: 278-284, 2004. (PMID
15032309).
80. Lim CJ and Shen WC: Transferrin-oligomers as potential carriers in anti-cancer drug delivery.
Pharm Res 21: 1985-1992, 2004.
81. Shen LJ, Beloussow K and Shen WC: Accessibility of endothelial and inducible nitric oxide
synthase to the intracellular citrulline-arginine regeneration pathway. Biochem Pharmacol 69: 97104, 2005.
82. Yuan L, Wang J and Shen WC: Reversible lipidization prolongs the pharmacological effects, plasma
duration and liver retention of octreotide. Pharm Res 22: 220-227, 2005.
83. Zaro JL and Shen WC: Evidence that membrane transduction of oligoarginine does not require
vesicle formation. Exp Cell Res 307: 164-173, 2005.
Curriculum Vitae, Wei-Chiang Shen
Page 17.
84. Lim CJ and Shen WC: Comparison of Monomeric and Oligomeric Transferrin as Potential Carrier
in Oral Delivery of Protein Drugs. J Controlled Release 106: 273-286, 2005. (PMID 15964654).
85. Bai Y, Ann DK and Shen WC: Recombinant granulocyte colony-stimulating factor-transferrin
fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci USA 102: 7292-7296, 2005. (PMID
15870205).
86. Zaro JL and Shen WC: Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting
proliferation of MCF7 cells. J Controlled Release 108: 409-417, 2005.
87. Shen LJ, Beloussow K and Shen WC: Modulation of arginine metabolic pathways as the potential
anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 231: 30-35, 2006.
88. Zaro JL, Rajapaksa T, Okamoto CT and Shen WC: Membrane transduction of oligoarginine in
HeLa cells is not mediated by macropinocytosis. Mol Pharm 3: 181-186, 2006.
89. Wang J, Hogenkamp DJ, Tran M, Li WY, Yoshimura RF, Johnstone TBC, Compton TR, Nguyen
OT, Parrott JA, Shen WC and Gee KW: Reversible aqueous lipidization of enkephalins yields orally
active analgesics. J Drug Targeting 14: 127-136, 2006.
90. Bai Y and Shen WC: Improving the oral efficacy of recombinant granulocyte colony-stimulating
factor and transferrin fusion protein by spacer optimization. Pharm Res 23: 2116-2121, 2006. (PMID
16952003).
91. Shen LJ and Shen WC: Drug Evaluation: ADI-PEG-20 – A pegylated arginine deiminase for
arginine-auxotrophic cancers. Current Opinion in Mol Therap 8: 240-248, 2006.
92. Bahhady R, Kim KJ, Borok Z, Crandall E and Shen WC: Enhancement of Insulin Transport across
Primary Rat Alveolar Epithelial Cell Monolayers by Endogenous Cellular Factor(s). Pharm Res 24:
1713-1719, 2007.
93. Lim CJ, Norouziyan F and Shen WC: Accumulation of Transferrin in Caco-2 Cells: A Possible
Mechanism of Intestinal Transferrin Absorption. J Controlled Release 122: 393-398, 2007. (PMID
17586083).
94. Norouziyan F, Shen WC and Hamm-Alvarez S: Rab11 is involved in transferrin trafficking
pathways in Caco-2 cells. Am J Physiol 294: C7-C21, 2008. (PMID 17959726).
95. Patel L, Kim KJ, Borok Z, Crandall E, Shen WC and Lee V: Molecular and Functional Expression
of Multidrug Resistance-Associated Protein-1 in Primary Cultured Rat Alveolar Epithelial Cells. J
Pharm Sci 97: 2340-2349, 2008. (
96. Bahhady R, Kim KJ, Borok Z, Crandall E and Shen WC: Characterization of Protein Factor(s) in
Rat Bronchoalveolar Lavage Fluid That Enhance Insulin Transport via Transcytosis across Primary
Rat Alveolar Epithelial Cell Monolayers. Eur J Pharm Biopharm 69: 808-816, 2008.
97. Yuan L, Wang J and Shen WC: Lipidization of human interferon-alpha: A new approach toward
improving the delivery of protein drugs. J Controlled Release 129: 11-17, 2008.
Curriculum Vitae, Wei-Chiang Shen
Page 18.
98. Yuan L, Wang J and Shen WC: Delivery of somatostatin analogues to liver via reversible
lipidization. Eur J Pharm Biopharm 70: 615-620, 2008.
99. Amet N, Lee HF and Shen WC: Insertion of the designed helical linker led to increased expression
of Tf- based fusion proteins. Pharm Res 26: 523-528, 2009. (PMID 19002568).
100. Barnes M and Shen WC: Disulfide and thioether linked cytochrome c-oligoarginine conjugates in
HeLa cells. Int J Pharm 369: 79-84, 2009.
101. Zaro J, Vekich J, Tran T and Shen WC: Nuclear localization of cell-penetrating peptides is
dependent on endocytosis rather than cytosolic delivery. Mol Pharm 6: 337-344, 2009.
102. Patel L, Wang J, Kim KJ, Borok Z, Crandall E and Shen WC: Conjugation with cationic cellpenetrating peptide increases pulmonary absorption of insulin. Mol Pharm 6: 492-503, 2009.
103. Amet N, Wang W and Shen WC: Human growth hormone–transferrin fusion protein for oral
delivery in hypophysectomized rats. J Controlled Release 141: 177-182, 2010. (PMID 19761807).
104. Chen X, Bai Y, Zaro J and Shen WC: Design of an in vivo cleavable disulfide linker in
recombinant fusion proteins. BioTechniques 49: 513-518, 2010. (PMID 20615204)
105. Fei L, Ren L, Zaro J and Shen WC: The influence of net charge and charge distribution on cellular
uptake and cytosolic localization of arginine-rich peptides. J Drug Targeting 19: 675-680, 2011.
(DOI: 10.3109/1061186X.2010.531729), 2011.
106. Chen X, Lee, HF, Zaro J and Shen WC: Effects of Receptor Binding on Plasma Half-life of
Bifunctional Transferrin Fusion Proteins. Mol Pharm 8: 457-465, 2011 (PMID 21291358).
107. Wang Y, Chen YS, Zaro JL and Shen WC: Receptor-Mediated Activation of a ProinsulinTransferrin Fusion Protein in Hepatoma Cells. J Controlled Release 155: 386-392, 2011 (PMID
21756950).
108. Mo R, Zaro J and Shen WC: Comparison of Cationic and Amphipathic Cell Penetrating Peptides
for siRNA Delivery and Efficacy. Mol Pharm 9(2): 299-309, 2012 (PMID: 22171592).
109. Mo R, Zaro J, Ou J and Shen WC: Effects of Lipofectamine 2000/siRNA Complexes on Autophagy
in Hepatoma Cells. Mol Biotechnol 51: 1-8, 2012 (PMID 22171592).
110. Kenien R, Zaro J and Shen WC: MAP-mediated nuclear delivery of a cargo protein. J Drug
Targeting 20: 329-337, 2012 (PMID: 22225540).
111. Zaro J, Fei L and Shen WC: Recombinant peptide constructs for targeted cell penetrating peptidemediated delivery. J Controlled Release 158: 357-361, 2012 (PMID: 22326404).
112. Bobst CE, Wang S, Shen WC and Kaltashov IA: Mass spectrometry study of a transferrin-based
protein drug reveals the key role of protein aggregation for successful oral delivery. Proc Natl Acad
Sci US 109: 13544-13548, 2012 (PMID: 22869744).
113. Kenien R, Shen WC and Zaro JL: Vesicle-to-cytosol transport of disulfide-linked cargo mediated by
an amphipathic cell penetrating peptide. J Drug Targeting 20: 793-800, 2012 (PMID: 22994388).
Curriculum Vitae, Wei-Chiang Shen
Page 19.
114. Zhang D, Lee HF, Pettit SC, Zaro J, Huang N and Shen WC: Characterization of transferrin
receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin
from rice (Oryza sativa L.). BMC Biotechnology 12:92, 2012 (DOI: 10.1186/1472-6750-12-92).
Reviews and chapters:
115. Shen WC: Radioimmunoassay of nicotinamide nucleotide analogs of nicotine and cotinine. IN:
Immunochemical Techniques, Methods in Enzymology, Vol. 84, J.J. Langone and H. Van Vunakis,
eds, Academic Press, New York, pp 650-654, 1982.
116. Ryser H J-P and Shen WC: Drug-poly(lysine) conjugates: Their potential for chemotherapy and
for the study of endocytosis. IN: Targeting of Drugs with Synthetic Systems, G. Gregoriadis, J.
Senior and G. Poste, eds., Plenum Publishing Co., pp 103-121, 1986.
117. Mandel R and Shen WC: Colorimetry. IN: Encyclopedia of Medical Devices and Instrumentation,
J.G. Webster, ed., John Wiley & Sons, Vol II, pp 771-779, 1988.
118. Shen WC: Drug-antibody conjugation - chemical aspects of antibody- mediated drug targeting of
drug. IN: Proceedings of PharmTech Conference. Aster Publishing Co., Eugene OR, pp 14-23,
1988.
119. Shen WC, Persiani S, Ballou B and Hakala TR: Antibodies as drug carriers for solid tumors.
Evaluation of drug-anti-SSEA-1 conjugates in the treatment of teratocarcinoma. IN: Targeted
Therapeutic Systems (P. Tyle and B.P. Ram, eds) Marcel Dekker, Inc. pp 289-304, 1989.
120. Shen WC, Wan J and Taub M: Transcellular Transport of protein-polymer conjugates in cultured
epithelial cells: The release of a protein from its polymeric carrier during transcytosis. IN:
Polymeric Drugs and Drug Delivery Systems, R. L. Dunn and R. Ottenbrite, eds., American
Chemical Society, pp 117-127, 1991.
121. Shen WC, Wan J and Ekrami H: Enhancement of polypeptide and protein absorption by
macromolecular carriers via endocytosis and transcytosis. Adv Drug Delivery Rev 8:93-113, 1992.
122. Shen WC and Lin YJ: Basic mechanisms in transepithelium transport enhancement. IN: Drug
Permeation Enhancement (DS Hsieh, ed), Marcel Dekker, Inc. pp 25-40, 1994.
123. Shen WC, Shah D, Taub ME and Wan J: Enhancement of transferrin receptor-mediated
transcytosis for transepithelial protein delivery. IN: Trends and Future Perspectives in Peptide and
Protein Drug Delivery (VHL Lee, M Hashida and Y Mizushima, eds), Harwood Academic
Publishers, pp 135-151, 1995.
124. Shen WC: Nuclear import of DNA -- the ultimate targeting in gene therapy, J Drug Targeting 5:1113, 1997.
125. Shen WC (Guest Editor): Receptor-Mediated Delivery of Macromolecular Drugs. Adv Drug
Delivery Rev 29: 195-196, 1998.
Curriculum Vitae, Wei-Chiang Shen
Page 20.
126. Shen WC, Wang J and Shen D: Reversible lipidization for the delivery of peptide and protein
drugs. IN: Peptide and Protein Drug Delivery (S Frokjaer, L Christrup and P Krogsgaard-Larsen,
eds), Munksgaard, Copenhagen, pp 397-410, 1998.
127. Shen WC: Membrane-associated protein thiol-disulfide interchange activity: a potential target
for anti-viral and anti-tumor drug design. J Drug Targeting 6: 387-389, 1999.
128. Rozenberg Y, Medvedkin V, Wang J and Shen WC: Alternative Gene Delivery. S.T.P. Pharma Sci
11: 21-30, 2001.
129. Shen WC: Oral peptide and protein delivery: unfulfilled promises? Drug Discovery Today 8: 607608, 2003.
130. Widera A, Norouziyan F and ShenWC: Mechanisms of TfR-mediated transcytosis and sorting in
epithelial cells and applications towards drug delivery. Adv Drug Delivery Rev 55: 1439-1466,
2003.
131. Shen LJ, Mandel R and Shen WC: Colorimetry. IN: Encyclopedia of Medical Devices and
Instrumentation (2nd edition), J.G. Webster, ed., John Wiley & Sons, pp. 187-197, 2006.
132. Patel L, Zaro J and Shen WC: Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical
Perspectives. Pharm Res 24: 1977-1992, 2007.
133. Amet N, Chen X, Lee HF, Zaro J and Shen WC: Transferrin receptor-mediated transcytosis for
gastrointestinal absorption of protein drugs. In: Targeted Delivery of Small and Macromolecular
Drugs (A. Narang and R.I. Mahato, eds) Taylor and Francis, pp. 31-52, 2010.
134. Zaro J, Wang J and Shen WC: Modifying the physiochemical nature of biodrugs by lipidization. In:
Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development (M. Morishita
and K. Park, eds) Informa Healthcare, N.Y., pp. 309-322, 2010.
135. Chen X, Zaro J and Shen WC: Pharmacokinetics of Recombinant Bifunctional Fusion Proteins.
Expert Opinion on Metabolism and Toxicology 8: 581-595, 2012. (PMID: 22418984).
136. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, et al. Guidelines for
the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544, 2012. (PMID:
22966490).
137. Hackett M, Zaro J, Shen WC and Cho MJ: Fatty Acids as Therapeutic Auxiliaries for Oral and
Parenteral Formulations. Adv Drug Delivery Rev (in press, DOI: 10.1016/j.addr.2012.07.012) 2012
(PMID: 22921839).
138. Chen X, Zaro J and Shen WC: Fusion Protein Linkers: Effects on Production, Bioactivity, and
Pharmacokinetics. In: Fusion Protein Technologies for Biopharmaceuticals: Applications and
Challenges (Stefan R. Schmidt, ed) Wiley-Blackwell, pp. 57-74, 2013.
139. Chen X, Zaro J and Shen WC: Fusion Protein Linkers: Property, Design and Functionality. Adv
Drug Delivery Rev (in press) 2013. (PMID: 23026637)
Curriculum Vitae, Wei-Chiang Shen
Page 21.
Textbook
1. Shen WC and Louie SG: Immunology for Pharmacy Students (Harwood Academic Publishers,
Amsterdam, the Netherlands), 1999.
Meeting Reports
1. Shen WC: Frontiers of Drug Development. IDrugs 2: 1002-1004, 1999.
2. Shen WC: ID Weekly Highlights. Week 36: 35-38, 2001.
3. Shen WC: Controlled Release Society - 29th Annual Meeting and Exposition. IDrugs 5: 908-909,
2002.
Book Review
1.
Shen WC: Neocarzinostatin: The past, present, and future of an anticancer drug. J Contr Rel 66:
322, 2000.
Published Abstracts
A total of 170 published abstracts in national and international meetings and conferences.